Definitely very expensive although I would be interested in seeing the details for how they arrive at that number and what exactly is included. For sure though it's a huge financial outlay and big commitment but I was only addressing the hiring of new staff.
Personally I'm very happy with the deal Neuren made for trofinetide and would be ok with them pursuing a similar strategy for 2591. That said I'm not sure what would happen if things get too complicated with the rights to the drug in the case of a company wanting to pursue a take over. Continued success in these phase two trials should only be a good thing but from an individual investor's standpoint it can vary from person to person depending on risk tolerance and desired timeframes
Definitely very expensive although I would be interested in...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.02 |
Change
-1.250(6.17%) |
Mkt cap ! $2.428B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $18.82 | $19.92M | 1.034M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1652 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.03 | 11612 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.10 |
Change
-1.250 ( 6.19 %) |
||||
| Open | High | Low | Volume | ||
| $20.39 | $20.46 | $18.83 | 299764 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| NEU (ASX) Chart |